v3.24.4

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current Assets:
Cash	$ 89,569	$ 9,422
Prepaid Expenses		30,234
Total Current Assets	89,569	39,656
Total Assets	89,569	39,656
Current Liabilities:
Short-term note payable	12,546	18,712
Short-term promissory note	55,000
Convertible notes payable	511,403	335,156
Total Current Liabilities	2,735,296	1,968,337
Stockholders’ Deficit:
Common Stock, par value $0.001; 300,000,000 shares authorized; 32,371,299 and 32,071,299 shares issued and outstanding, respectively	32,371	32,071
Additional paid-in capital	14,374,647	14,339,323
Accumulated deficit	(17,052,745)	(16,300,075)
Total Stockholders’ Deficit	(2,645,727)	(1,928,681)
Total Liabilities and Stockholders’ Deficit	89,569	39,656
Series A Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Convertible Preferred Stock, value
Series B Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Convertible Preferred Stock, value
Nonrelated Party [Member]
Current Liabilities:
Accounts payable	1,231,064	961,708
Related Party [Member]
Current Liabilities:
Accounts payable	809,971	537,449
Accrued salaries, related party	$ 115,312	$ 115,312

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Vicapsys Life Sciences, Inc. 10-Q